Dr. Michael Peluso, a researcher at the University of California, established the first long COVID tissue bank six years ago to accelerate understanding of the disease that affects millions globally. His team collects and analyzes biological samples from long COVID patients, creating a repository that enables scientists to study the condition at the cellular and molecular level.
Long COVID, the persistent illness that follows acute COVID-19 infection, produces debilitating symptoms including fatigue, brain fog, and exercise intolerance that can last months or years. The tissue bank approach differs from traditional research by providing actual biological material for examination rather than relying solely on patient reports or imaging studies.
Peluso's work focuses on identifying the physical mechanisms underlying long COVID. His team analyzes tissue samples to detect viral particles, immune dysfunction, or metabolic abnormalities that might explain why some people develop chronic symptoms. This hands-on examination reveals patterns invisible in conventional clinical assessments.
The tissue bank model addresses a critical gap in long COVID research. Previous studies relied heavily on blood tests and symptom tracking, missing potential damage or dysfunction in specific organs and tissues. By collecting samples directly from affected individuals, Peluso's team can investigate whether persistent viral infection, immune dysregulation, or tissue damage drives the disease.
Early findings from his research suggest long COVID involves complex biological changes rather than psychological factors. His team has documented mitochondrial dysfunction and metabolic alterations in some patients, providing biological evidence for the condition's legitimacy.
The repository continues expanding, with more patients contributing samples and more researchers accessing the biobank for their own investigations. This collaborative approach accelerates discovery compared to individual labs working independently. Multiple research groups now use Peluso's tissue samples to test different hypotheses about long COVID's causes.
The ultimate goal remains developing treatments targeting the specific biological mechanisms driving long COVID. Without understanding what happens at the cellular level, developing effective interventions remains difficult.